Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of IkT-148009 in Untreated Parkinson's Disease

X
Trial Profile

A Phase 2 Study of IkT-148009 in Untreated Parkinson's Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risvodetinib (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms 201 trial
  • Sponsors Inhibikase Therapeutics
  • Most Recent Events

    • 27 Mar 2024 According to an Inhibikase therapeutics media release, As of March 22, 2024, 73 participants have been enrolled, 20 prospective participants are in medical screening and 48 potential participants are being evaluated for suitability to initiate medical screening. Additionally, 34 participants have completed the 12-week dosing period. 15 mild and 2 moderate adverse events that may have been related to Risvo have been reported thus far in the trial
    • 07 Mar 2024 According to an Inhibikase therapeutics media release, Dr. Milton Werner, President and Chief Executive Officer of Inhibikase Therapeutics, will present an update on the of the 201 Trial at the 2024 AD/PD Meeting being held March 5-9, 2024
    • 24 Feb 2024 According to an Inhibikase therapeutics media release, as of 24 Feb 2024, 59 participants have been enrolled, 19 prospective participants are in medical screening and 54 potential participants are being evaluated for suitability to initiate medical screening. 25 participants have completed the 12 week dosing period. 10 mild and 1 moderate adverse event that might be related to treatment have been reported across all study participants.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top